Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 24,861 shares of the business’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the transaction, the insider now owns 140,684 shares in the company, valued at approximately $23,208,639.48. This trade represents a 15.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Solomon Moshkevich also recently made the following trade(s):
- On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The stock was sold at an average price of $166.59, for a total value of $809,294.22.
- On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $141,379.16.
Natera Stock Down 2.5 %
Shares of NASDAQ:NTRA opened at $167.61 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock’s 50-day moving average price is $166.20 and its two-hundred day moving average price is $136.07. Natera, Inc. has a 12-month low of $62.96 and a 12-month high of $183.00.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NTRA. Chartwell Investment Partners LLC grew its holdings in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Cerity Partners LLC increased its position in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after acquiring an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Natera in the 3rd quarter valued at $385,000. Everence Capital Management Inc. acquired a new position in shares of Natera during the 4th quarter valued at $573,000. Finally, First Turn Management LLC purchased a new stake in Natera during the 3rd quarter worth $19,760,000. Institutional investors and hedge funds own 99.90% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have commented on NTRA. Craig Hallum raised their target price on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Guggenheim boosted their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Robert W. Baird increased their target price on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. The Goldman Sachs Group boosted their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Finally, StockNews.com cut Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $162.94.
Read Our Latest Stock Analysis on Natera
About Natera
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
See Also
- Five stocks we like better than Natera
- Consumer Discretionary Stocks Explained
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What is an Earnings Surprise?
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How to Buy Cheap Stocks Step by Step
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.